Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Hypertension (HTN), Hyperhomocysteinemia...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This prospective single-center observational study aims to evaluate the relationship between elevated plasma homocysteine levels and early echocardiographic abnormalities in patients with newly diagnosed essential hypertension. Adult patients diagnosed with essential hypertension within the previous 6 months will undergo clinical assessment, ambulatory blood pressure monitoring, electrocardiography, laboratory testing, and comprehensive transthoracic echocardiography including diastolic function assessment and strain analysis when image quality is adequate. Participants will be classified according to plasma homocysteine level using, and patients with elevated and normal homocysteine levels will be compared with respect to diastolic dysfunction and left ventricular and left atrial global longitudinal strain parameters. Clinical, laboratory, and echocardiographic data will also be used to develop a machine-learning based model for prediction of H-type hypertension.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Homocysteine Measurement and Echocardiography — Peripheral venous blood sampling for plasma homocysteine measurement and comprehensive transthoracic echocardiography including diastolic function assessment and strain analysis.

Primary Outcomes

  • Presence of Early Left Ventricular Diastolic Dysfunction (Baseline assessment at enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-02
Completion: 2028-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Necmettin Erbakan University
Principal Investigators:
  • yunus emre yavuz, MD (PRINCIPAL_INVESTIGATOR) - Necmettin Erbakan University
Contact Information
Study Contact:
yunus emre yavuz, MD
+90 5306069194
eyavuz@erbakan.edu.tr
YUNUS EMRE YAVUZ, MD
+905306069194
eyavuz@erbakan.edu.tr
Necmettin Erbakan University Meram Faculty of Medicine
Interventions
  • Diagnostic Test: Homocysteine Measurement and Echocardiography — Peripheral venous blood sampling for plasma homocysteine measurement and comprehensive transthoracic echocardiography including diastolic function assessment and strain analysis.
Study Locations (1 sites)
Necmettin Erbakan University Meram Faculty of Medicine, Konya, Meram 42080 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or older * Newly diagnosed essential hypertension within the previous 6 months * Ability and willingness to provide informed consent * Availability for clinical evaluation, laboratory testing, ambulatory blood pressure monitoring, electrocardiography, and transthoracic echocardiography Exclusion Criteria: * Resistant hypertension * Secondary hypertension * Acute coronary syndrome within the previous 6 months * Major surgery within the previous 6 months * Known heart failure * Pulmonary hypertension * Congenital heart disease * Atrial fibrillation or atrial flutter * Moderate or severe valvular heart disease * Chronic kidney disease * Anemia * Current folate, vitamin B12, or vitamin B6 supplementation or treatment * Inadequate echocardiographic image quality for strain analysis * Known systemic conditions that may significantly affect plasma homocysteine levels
Conditions Stress
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial will investigate whether a powdered prebiotic fibre blend, at two doses, can improve perceived stress levels in healthy adults with mild-severe stress levels.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: Prebiotic fibre blend — A blend of prebiotic fibres in a powdered supplement form.
  • Dietary Supplement: Maltodextrin (Placebo) — Maltodextrin powder

Primary Outcomes

  • Perceived Stress (Baseline and 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-01
Completion: 2028-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Myota GmbH
Collaborators: University of Reading
Contact Information
Study Contact:
Thomas Gurry, PhD
797908227
thomas@myotahealth.com
Caitlin Hall, PhD
7830709854
caitlin@myotahealth.com
BALANCE Study Site
Interventions
  • Dietary Supplement: Prebiotic fibre blend — A blend of prebiotic fibres in a powdered supplement form.
  • Dietary Supplement: Maltodextrin (Placebo) — Maltodextrin powder
Study Locations (1 sites)
BALANCE Study Site, London, EC2A 4BQ United Kingdom
Eligibility Criteria
Inclusion Criteria: * Aged 18-50 years of age * Capacity to give informed consent to participate in the study * Able to comply with study requirements and visits * Meet the criteria for mild-severe stress levels (scores between 15-33) as assessed by DASS-42 Stress Subscale * Normal or corrected to normal vision and/or hearing Exclusion Criteria: * Current smoker * Having food allergies and/or intolerances * Current diagnosis of Type 1 or 2 diabetes, cardiometabolic disease, or psychiatric or neurological conditions (e.g. schizophrenia, dementia) including eating disorders * Current or previous diagnosis of depression in past 6 months * Currently receiving medications that lower cholesterol, blood pressure, blood glucose levels, or improve insulin sensitivity * Receiving antidepressant or anti-anxiety medications or treatments * Receiving hormonal birth control * Perimenopause or menopause * Pregnancy, lactation, or an intent to become pregnant during the course of the study * Continuous antibiotic use for \> 3 days within 1 month prior to enrolment * Continuous use of weight-loss drug for \> 1 month before screening * Major change in dietary intake in past month (e.g. excluding whole food groups) * Consuming a restricted diet, including a vegan, vegetarian, and ketogenic diet * Currently consuming daily prebiotic or probiotic supplements * Any significant GI condition affecting absorption including (but not limited to) inflammatory bowel disease, weight loss surgery, irritable bowel syndrome. * Active cancer, or treatment for any cancer, in last 3 years * Consuming more than 20g of fibre a day as assessed by the FiberScreen

MedlyPeds Feasibility Study

NCT07556185
Recruiting
Conditions Pediatric Heart Failure, Congenital Hear...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

SickKids and UHN have developed MedlyPeds which is a smart phone application designed to remotely monitor patients with heart disease. This is a feasibility study which will enroll up to 30 patients with different types of heart disease to see which patient types may benefit the most from MedlyPeds if it were to be used for clinical monitoring. The study is gathering feedback about the app from patients, parents and clinicians to confirm how it needs to be modified to better serve the purpose in a future trial.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: MedlyPeds App — The mobile phone-based telemonitoring system (MedlyPeds) will enable cardiac patients to monitor their weight, blood pressure, and heart rate, using wireless home medical devices. In addition, they will answer questions about their symptoms and wellness using their mobile phone. The device measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated and individualized self-care messages, developed with the assistance of healthcare providers, will subsequently be sent to the patient based on the readings and reported symptoms.

Primary Outcomes

  • Percentage of MedlyPeds App Daily Check-In Completion (3 months)
  • Feasibility and acceptability of Medly Peds (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07
Completion: 2029-12
Eligibility
Age: 8 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Hospital for Sick Children
Collaborators: University Health Network, Toronto
Contact Information
Study Contact:
Diana Balmer-Minnes
416-813-7654
diana.balmer-minnes@sickkids.ca
Diana Balmer-Minnes
4169316961
diana.balmer-minnes@sickkids.ca
The Hospital for Sick Children
Interventions
  • Device: MedlyPeds App — The mobile phone-based telemonitoring system (MedlyPeds) will enable cardiac patients to monitor their weight, blood pressure, and heart rate, using wireless home medical devices. In addition, they will answer questions about their symptoms and wellness using their mobile phone. The device measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated and individualized self-care messages, developed with the assistance of healthcare providers, will subsequently be sent to the patient based on the readings and reported symptoms.
Study Locations (1 sites)
The Hospital for Sick Children, Toronto, Ontario M5G1X8 Canada
Eligibility Criteria
Inclusion Criteria: 1. Consent provided. 2. Aged 8-18 years of age. 3. Ability to comply with using Medly (ex. able to stand on the weight scale, able to answer symptom questions, etc.) 4. Followed at the Hospital for Sick Children Cardiology Clinic for any of the following reasons: 1. Heart failure of any etiology 2. Congenital heart disease 3. Acquired heart disease (eg. Kawasaki disease, rheumatic heart disease, connective tissue disorders etc) 4. Pulmonary hypertension 5. Post-cardiac surgery including heart transplant and ventricular assist devices Exclusion Criteria: 1. Unable to read or write in English. 2. Participating in another clinical trial that may confound the results.\* \*Participant may be re-screened for eligibility at a later date.
Conditions Depression - Major Depressive Disorder, ...
Phase NA
Enrollment 44
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This research explores the potential of retinal ganglion cells (RGCs), particularly intrinsically photosensitive RGCs (ipRGCs), as biomarkers for predicting response to transcranial magnetic stimulation (TMS) in treatment-resistant depression (TRD). We also aim to assess the impact of TMS treatment on RGCs and ipRGCs in TRD patients, investigating associations with clinical improvements and cognitive status. A clinical trial involving 44 patients with treatment-resistant depression (TRD) will be conducted. All participants will receive rTMS targeting the dorsolateral prefrontal cortex (DLPFC). Data will be collected pre- and post-intervention, as well as at a 2-month follow-up, using multiple outcome measures, including the post-illumination pupil response (PIPR). The project seeks to confirm the effectiveness of TMS and the potential of RGCs/ipRGCs as predictors of treatment response, thereby facilitating the development of personalized treatment strategies for TRD patients undergoing rTMS therapy.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Repetitive transcranial magnetic stimulation (rTMS) — Each participant's resting motor threshold (RMT) will be determined by visual observation in accordance with standard clinical practice. Intermittent theta-burst stimulation (iTBS) will be delivered over the left dorsolateral prefrontal cortex (DLPFC) using these parameters: stimulation intensity 120% RMT; bursts at 50 Hz; 2 s on and 8 s off; 600 pulses per session; total stimulation time approximately 3 minutes per session. Stimulation will be delivered using a MagPro X100 stimulator with MagOption, equipped with a B70 butterfly-shaped coil with static cooling (MagVenture, Denmark). Treatment will comprise 20 sessions, delivered once daily on weekdays.

Primary Outcomes

  • Chromatic pupillometry (Baseline (pre-intervention), Post-intervention (a day immediately after the end of intervention) and Follow-up (2 months after the end of intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-15
Completion: 2027-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 44 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Polytechnic Institute of Porto
Collaborators: Hospital de Sao Joao, Porto
Principal Investigators:
  • Catarina C Mateus, PhD (STUDY_DIRECTOR) - Polytechnic Institute of Porto
Contact Information
Study Contact:
Inês Duarte D Pais, MSc
+351 917750656
idp@ess.ipp.pt
Catarina C Mateus, PhD
+351 913474780
cms@ess.ipp.pt
Nuno B Rocha, PhD
+351 913474780
nrocha@ess.ipp.pt
RISE-Health, Center for Translational Health and Medical Biotechnology Research (TBIO), School of Health, Polytechnic of Porto
Interventions
  • Device: Repetitive transcranial magnetic stimulation (rTMS) — Each participant's resting motor threshold (RMT) will be determined by visual observation in accordance with standard clinical practice. Intermittent theta-burst stimulation (iTBS) will be delivered over the left dorsolateral prefrontal cortex (DLPFC) using these parameters: stimulation intensity 120% RMT; bursts at 50 Hz; 2 s on and 8 s off; 600 pulses per session; total stimulation time approximately 3 minutes per session. Stimulation will be delivered using a MagPro X100 stimulator with MagOption, equipped with a B70 butterfly-shaped coil with static cooling (MagVenture, Denmark). Treatment will comprise 20 sessions, delivered once daily on weekdays.
Study Locations (1 sites)
RISE-Health, Center for Translational Health and Medical Biotechnology Research (TBIO), School of Health, Polytechnic of Porto, Porto, Porto District 4200-072 Portugal
Eligibility Criteria
Inclusion Criteria: * Diagnosis of MDD, confirmed via the structured clinical interview; * TRD type; * Age between 18-65 years; * Visual acuity of 20/32 or better. Exclusion Criteria: * Prior rTMS treatment; * Contraindications for TMS; * Psychiatric disorders other than MDD; * Systemic diseases affecting the eyes (e.g., diabetes mellitus); * Ocular conditions; * Head injuries causing loss of consciousness; * Current or past alcohol/substance dependence within 6 months; * Neurodegenerative diseases; * Major neurological illnesses; * Use of medications affecting iris mechanics or the autonomic nervous system.
Conditions Diabetes Type 2, Kidney Disease
Phase NA
Enrollment 104
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates whether a digital patient education program can improve adherence to KDIGO 2022 dietary recommendations (low sodium and optimal protein intake) among patients with type 2 diabetes and chronic kidney disease (eGFR 30-59 ml/min).

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: StenoFood App — Digital patient education program (app-based) with dietary guidance and self-monitoring tools

Primary Outcomes

  • Change in sodium excretion between measurements at baseline and 6 months follow-up (6 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-20
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 104 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Steno Diabetes Center Copenhagen
Contact Information
Study Contact:
Kirsten S Bjørnsbo, phd
0045 20169134
kirsten.bjoernsbo@regionh.dk
Steno Diabetes Center Copenhagen,
Signe Lautrup-Nielsen, MSc
0045 91172915
signe.lautrup-nielsen@regionh.dk
Steno Diabetes Center Copenhagen,
Thomas P Almdal, MD
Steno Diabetes Center Copenhagen,
Interventions
  • Device: StenoFood App — Digital patient education program (app-based) with dietary guidance and self-monitoring tools
Study Locations (2 sites)
Steno Diabetes Center Copenhagen,, Herlev, Captial Region of Denmark 2730 Denmark
Nordsjællands Hospital, Hillerød, Hillerød, Captial Region of Denmark 3400 Denmark
Eligibility Criteria
Inclusion Criteria: * Type 2 diabetes (ICD-10 DE11.x) * Age 18-74 years * BMI \< 35 kg/m² * eGFR 30-59 ml/min and UACR \> 30 mg/g * Stable medication for ≥3 months * Ability to read and understand Danish Exclusion Criteria: * Type 1 diabetes or other diabetes types * Current vegan diet * Active cancer * Short bowel syndrome or celiac disease * Use of sodium chloride tablets * No access to digital platform (intervention group only)
Conditions Breast Cancer, Ovarian Cancer, Endometri...
Phase PHASE1
Enrollment 63
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors including breast cancer. Participants enrolled in the study have advanced disease that is not amendable to curative treatment and whose tumors harbor alterations in the PI3KCA gene.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: RGT-490 — Oral tablets

Primary Outcomes

  • Incidence of dose limiting toxicities (DLTs) (4 weeks (1 cycle))
  • Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) (Every cycle (4-week cycles) until study discontinuation, approximately 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-06
Completion: 2028-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 63 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Regor Pharmaceuticals Inc.
Contact Information
Study Contact:
Sarah Wheeler
857-331-3898
Sarah.Wheeler@regor.com
Regor Pharmaceuticals Central Office
617-315-9070
RGT-490-101@regor.com
Interventions
  • Drug: RGT-490 — Oral tablets
Study Locations (5 sites)
START Los Angeles, Los Angeles, California 90025 United States
The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 United States
NEXT Houston, Houston, Texas 77054 United States
NEXT San Antonio, San Antonio, Texas 78229 United States
NEXT Virginia, Fairfax, Virginia 22031 United States
Eligibility Criteria
Inclusion Criteria: * Adults with metastatic or locally advanced, unresectable solid tumors that have progressed on or after at least one available therapy. * Presence of one or more documented activating PIK3CA mutation in tumor tissue and/or blood. * At least 1 measurable lesion or evaluable disease per RECIST v1.1. * An ECOG performance status of 0 or 1. * Adequate organ function Exclusion Criteria: * Diabetes mellitus requiring anti-hyperglycemic medication. * Prior treatment with PI3Kα inhibitors * Symptomatic, untreated, or uncontrolled central nervous system metastases. * Receipt of any local or systemic anticancer therapy or investigational anticancer agent within a protocol-defined washout period prior to study treatment. * Unresolved clinically significant toxicities from prior anticancer therapy * History of a another malignancy within 2 years prior to screening (exception adequately treated cancers).
Conditions Diabete Type 2, Cardio Vascular Disease
Phase Not Applicable
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to isolate endothelial progenitor cells (EPCs) from participants with type 2 diabetes (T2D) and cardiovascular complications and to comprehensively characterize EPC dysfunction. Specifically, the study will evaluate maladaptive angiocrine signaling, calcium signaling pathways, and the role of inflammation in EPC function and the progression of atherosclerosis during T2D development. A sub-study will assess EPC functionality by examining endothelial nitric oxide synthase (eNOS) expression and activity, as well as the effectiveness of in vitro eNOS gene enhancement.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Characterization of EPCs dysregulation in Type 2 diabetes (Following the EPC isolation (15 - 20 days).)
  • Functional Analysis of inflammatory responses in Endothelial Progenitor Cells in type 2 Diabetes with cardiovascular complications (Following the EPC isolation (15 - 20 days))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-11-17
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Cornell Medical College in Qatar
Collaborators: Hamad Medical Corporation
Principal Investigators:
  • Charbel Abi Khalil, MD,PhD (PRINCIPAL_INVESTIGATOR) - Weill Cornell Medicine-Qatar
Contact Information
Study Contact:
Jassim Al Suwaidi, MD
+974 4439 5354
jalsuwaidi@hamad.qa
Hamad Medical Corporation
Interventions
N/A
Study Locations (1 sites)
Hamad Medical Corporation, Doha, Qatar
Eligibility Criteria
Inclusion Criteria: * T2D * Males and females * Older than 18 years of age * Willingness to participate in the study and provide written consent form * Consent to having peripheral blood withdrawals and urine collection for the study requirement. Exclusion Criteria: * Unable to meet the inclusion criteria * Type I diabetes, MODY diabetes or other form of diabetes * Active infection, inflammation, cancer or acute illness of any kind (other than a cardiovascular complication of diabetes if applicable in the group they are assigned to). * Chronic inflammation (eg. auto-immune diseases) or infections (eg. HIV, chronic hepatitis). * Evidence of malignancy within the past 5 years
Conditions Pulmonary Arterial Hypertension
Phase PHASE3
Enrollment 344
Locations 26 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Treprostinil Palmitil Inhalation Powder — Oral inhalation using a capsule-based dry powder inhaler device.
  • Drug: Placebo — Oral inhalation using a capsule-based dry powder inhaler device.

Primary Outcomes

  • Change in 6-Minute Walk Distance (6MWD) Measured at 1 to 3 Hours Post-Dose From Baseline at Week 24 (Baseline, Week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-07-21
Completion: 2029-01-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 344 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Insmed Incorporated
Contact Information
Study Contact:
Insmed Medical Information
18444467633
medicalinformation@insmed.com
Interventions
  • Drug: Treprostinil Palmitil Inhalation Powder — Oral inhalation using a capsule-based dry powder inhaler device.
  • Drug: Placebo — Oral inhalation using a capsule-based dry powder inhaler device.
Study Locations (26 sites)
USA012, Los Angeles, California 90027 United States
USA008, Santa Barbara, California 93105 United States
USA005, Torrance, California 90502 United States
USA010, Kansas City, Kansas 66160 United States
USA028, Omaha, Nebraska 68198-6450 United States
USA013, Rochester, New York 14642 United States
USA006, Philadelphia, Pennsylvania 19140 United States
USA007, Anderson, South Carolina 29621 United States
ARG001, Buenos Aires, Buenos Aires F.D. C1425AIN Argentina
ARG004, Río Cuarto, Córdoba Province X5080AEV Argentina
Eligibility Criteria
Inclusion Criteria * Participants must have a diagnosis of World Health Organisation (WHO) Group 1 pulmonary hypertension (PAH) in any of the following subtypes, in accordance with European Society of Cardiology European Respiratory Society (ESC/ERS) Guidelines: * Idiopathic PAH * Heritable PAH * Drug/toxin-induced PAH * Connective tissue disease (CTD)-associated PAH * PAH associated with congenital heart disease-related to simple systemic-to-pulmonary shunt at least 1 year following repair. * PAH diagnosis for at least 3 months prior to Screening. * New York Heart Association (NYHA) or World Health Organization (WHO) functional class II-IV. * Participants must be on stable PAH therapy consisting of 1 to 3 medications from the following classes: * Endothelin receptor antagonists (eg, ambrisentan, bosentan, macitentan) for at least 90 days prior to Screening with the last 30 days on stable dose * Phosphodiesterase type 5 inhibitors (eg, sildenafil, tadalafil) for at least 90 days prior to Screening with the last 30 days on stable dose * Guanylate cyclase stimulator (eg, riociguat) for at least 90 days prior to Screening with the last 30 days on stable dose * Activin signaling inhibitor (e.g., sotatercept) for at least 6 months prior to Screening, with the last 3 months on stable dose and meeting all the following conditions: * no active clinically significant bleeding (eg, epistaxis and gingival bleeding requiring medical interventions) within the past 3 months. * no history of major bleeding events or risks (eg, gastrointestinal or intracranial bleeding) within the past 6 months. * platelet counts ≥100,000 per microlitre (μL) at Screening * For both 6-minute walk tests (6MWTs), the values of 6-minute walk distance (6MWD) should be ≥ 150 and ≤ 450 meters at Screening. * Right heart catheterization (RHC) at Screening (or within 6 months prior to Screening, if available). Prior RHC may be used provided there has been no change in background PAH therapy and doses. The RHC must meet all of the following hemodynamic criteria: * Mean pulmonary arterial pressure (PAP) \>20 millimetre of mercury (mmHg) at rest. * pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) ≤15 mmHg. * pulmonary vascular resistance (PVR) of ≥5 wood units (WU). Exclusion Criteria * Diagnosis of PH WHO Groups 2, 3, 4, or 5, or subtypes of PH WHO Group 1 other than described in inclusion criterion 2 (eg, human immunodeficiency virus (HIV), complex congenital heart disease-associated PAH, portal hypertension-associated PAH, pulmonary veno-occlusive disease, Schistosomiasis associated PAH). * Clinically significant left heart disease, including left-sided valvular disease, left ventricular systolic or diastolic dysfunction, echocardiographic findings suggestive of post-capillary pulmonary hypertension, unstable ischemic heart disease, or unstable arrhythmias. * Evidence of airflow obstruction defined by forced expiratory volume in 1 second (FEV1) per forced vital capacity (FVC) \<0.7. * Evidence of significant restrictive lung disease as evidenced by FVC \<70% predicted normal. * Evidence of chronic thromboembolic disease or recent (within 6 months of Screening) acute pulmonary embolism. * Known hypersensitivity or contraindication to treprostinil or TPIP or TPIP formulation excipients (e.g., mannitol, leucine). * Any other medical or psychological condition including relevant laboratory abnormalities at Screening that, in the opinion of the Investigator, suggest a new and/or insufficiently understood disease and/or may present an unreasonable risk to the study participant as a result of his/her participation in this clinical trial, may impede their ability complete the study or the study assessments or confound the outcomes of the trial. Note: Other protocol-defined inclusion/exclusion criteria may apply.
Conditions Primary Open Angle Glaucoma, Obstructive...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

glaucoma is prevalent among obstructive sleep apnea (OSA). contnous passive airway pressure is main treatment of OSA. lifestyle corrections also recommended

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: lifetyle corrections and CPAP — twenty glaucoma patients (high tension priamry open angle form) with OSA, intraocular pressure more than 21 mmHg, and obesity will be involved in group I will apply CPAP during night sleeping daily for three month. group I will apply lifestyle corrections (low calories diet intake and 3-session per-week 40-minute treadmill walking for three month.
  • Other: CPAP — twenty glaucoma patients (high tension priamry open angle form) with OSA, intraocular pressure more than 21 mmHg, and obesity will be involved in group II will apply CPAP during night sleeping daily for three month.

Primary Outcomes

  • Intraocular pressure (it will be measured after 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-04
Completion: 2026-07-20
Eligibility
Age: 30 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cairo University
Principal Investigators:
  • Ali MA Ismail, lecturer (PRINCIPAL_INVESTIGATOR) - Cairo University
Contact Information
Study Contact:
Ali MA Ismail, lecturer
01005154209
ali.mohamed@pt.cu.edu.eg
ali mohamed, lecturer
0201031321109
fatmaraed1994@gmail.com
ali ismail, lecturer
02 01005154209
ali.mohamed@pt.cu.edu.eg
Cairo University
Interventions
  • Behavioral: lifetyle corrections and CPAP — twenty glaucoma patients (high tension priamry open angle form) with OSA, intraocular pressure more than 21 mmHg, and obesity will be involved in group I will apply CPAP during night sleeping daily for three month. group I will apply lifestyle corrections (low calories diet intake and 3-session per-week 40-minute treadmill walking for three month.
  • Other: CPAP — twenty glaucoma patients (high tension priamry open angle form) with OSA, intraocular pressure more than 21 mmHg, and obesity will be involved in group II will apply CPAP during night sleeping daily for three month.
Study Locations (1 sites)
Cairo University, Giza, Dokki Egypt
Eligibility Criteria
Inclusion Criteria: * Obstructive sleep apnea patients * obese patients * glaucoma (open angle form with ocular hyoertension) Exclusion Criteria: cardiac patients renal patients hepatic patients
Conditions Breast Cancer, Prostate Cancer
Phase PHASE1, PHASE2
Enrollment 23
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh peripheral blood mononuclear cells (HER2 FPBMC) for patients with metastatic breast or prostate cancer. Participants receive 5 weekly doses of CD33 FPBMC by intravenous infusion followed by 4 infusions every other week.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: HER2 FPBMC — Participants will receive 5 weekly infusions of HER2 FPBMC infusions followed by 4 additional infusions every other week.

Primary Outcomes

  • Dose limiting toxicities (DLTs) (During the first 5 infusions (5 weeks) for each participant)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-06
Completion: 2032-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 23 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Virginia
Principal Investigators:
  • Paul Viscuse, MD (PRINCIPAL_INVESTIGATOR) - University of Virginia
Contact Information
Study Contact:
Ashley Lamont
(434) 243-6377
ZWZ6JM@uvahealth.org
Laura Livingston
434-882-5578
LL9TE@uvahealth.org
Ashley Lamont
434-409-5009
zwz6jm@UVAHealth.org
University of Virginia
Interventions
  • Drug: HER2 FPBMC — Participants will receive 5 weekly infusions of HER2 FPBMC infusions followed by 4 additional infusions every other week.
Study Locations (1 sites)
University of Virginia, Charlottesville, Virginia 22903 United States
Eligibility Criteria
Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Age ≥ 18 years at the time of signing informed consent 4. Expected survival ≥ 3 months in the judgment of the investigator 5. ECOG PS 0-1 6. Adequate Organ Function per the following criteria (within 10 days of study registration): * Absolute lymphocyte count ≥ 400/mm3 * Absolute neutrophil count ≥ 1000/mm3 * Platelets ≥ 75,000/mm3 * Hemoglobin ≥ 9g/dL * Serum creatinine \< 2.0 mg/dL OR measured or calculated creatinine clearance ≥ 50 ml/mm * Total bilirubin ≤ mg/dL * Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) \< 5.0 times normal 7. Agreement to adhere to Lifestyle Considerations throughout study duration 8. A diagnosis of either of the following: a. Prostate Cancer: i. Histological and/or cytological confirmation of prostate adenocarcinoma. ii. Participants must have progressive mCRPC at screening iii. Serum testosterone levels \<50 ng/dL during screening. iv. Must have progressed on at least one prior ARPI (abiraterone acetate, enzalutamide, apalutamide, or darolutamide). v. Participants must have ≥1 metastatic lesion that is present on baseline CT, MRI, or bone scan obtained ≤28 days prior to registration. b. Breast Cancer i. Histological and/or cytological confirmation of invasive breast cancer. ii. Participants must have previously treated metastatic breast cancer at screening. Metastatic breast cancer must be evaluable by RECIST 1.1 criteria. iii. Must have progressed on at least two prior endocrine or targeted therapies or at least two lines of cytotoxic chemotherapy. If HER2 positive, then must have progressed on or been intolerant of at least one HER2 targeted therapy. iv. Participants must have ≥1 metastatic lesion that is present on baseline CT, MRI, or bone scan obtained ≤28 days prior to registration. Exclusion Criteria: 1. Pregnancy (must have negative pregnancy test within 7 days prior to study registration) or lactation 2. History of a recent myocardial infarction (within one year) or a past myocardial infarction (more than one year prior to enrollment) who are actively requiring nitroglycerine more than once per week 3. Inadequate cardiac function, as defined as any of the following: * Uncontrolled angina or severe ventricular arrhythmias * Clinically significant pericardial disease * History of myocardial infarction (MI) in the last year before registration * Class 3 or higher New York Heart Association Congestive Heart Failure 4. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study registration. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. 5. Serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to registration 6. Active liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis 7. Is HIV positive or has evidence of active Hepatitis C virus or active Hepatitis B virus. 8. Active bleeding or a pathological condition that is associated with a high risk of bleeding (therapeutic anticoagulation is allowed) 9. Has an active infection requiring systemic therapy 10. A serious uncontrolled medical disorder that in the opinion of the Investigator may be jeopardized by the treatment with protocol therapy 11. Has a known history of active TB (Bacillus Tuberculosis) 12. Has received a live vaccine within 30 days of study registration. 13. Treatment with any investigational agent within 3 weeks prior to study registration 14. Active second malignancy requiring systemic treatment. Exceptions include basal cell carcinoma of the skin, treated cervical cancer, and squamous cell carcinoma of the skin 15. Has active autoimmune disease that has required systemic treatment in the 2 years prior to registration (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. 16. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator. 17. Patient may be excluded if, in the opinion of the PI and investigator team, the patient is not capable of being compliant Additional Exclusion Criteria for Patients with Prostate Cancer: 1. Has small cell neuroendocrine carcinoma (pure or mixed) on prior or current histologic evaluation of primary or metastatic lesions 2. Has an actionable BRCA1 or BRCA2 alteration, for which approved therapies are available, e.g., PARP inhibitors, unless these therapies are not appropriate for the participant as determined by the investigator or the participant refuses such therapy. Participants with one of these mutations and who have progressed on targeted therapy are eligible. Additional Exclusion Criteria for Patients with Breast Cancer: 1. Has an actionable BRCA1 or BRCA2 alteration, for which approved therapies are available, e.g., PARP inhibitors, unless these therapies are not appropriate for the participant as determined by the investigator or the participant refuses such therapy. Participants with one of these mutations and who have progressed on targeted therapy are eligible. 2. Participants in visceral crisis at risk of immediately life-threatening complications in the short term, including participants with massive uncontrolled effusions (pleural, pericardial, and peritoneal), pulmonary lymphangitis, or liver involvement \> 50%.
Conditions Hypertension
Phase NA
Enrollment 607
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this pre-post study is to assess the risk of hyperkalemia in adults with hypertension on medication in Bangladesh. The main questions it aims to answer are: Is the risk of hyperkalemia after the initiation of Low Sodium Salt Substitute (LSSS) in people on antihypertensive medication (especially RASi) large enough to be concerned about its broad use in this population? Does initiation of LSSS correct hypokalemia in people on antihypertensive medication (especially RASi) with low serum potassium levels? Participants will be asked to reduce overall salt intake and to use LSSS on every occasion where regular salt would normally be used, including as cooking salt.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Low-sodium salt substitute — The low sodium salt substitute contains 25% potassium chloride (KCl range; 20%-35%)

Primary Outcomes

  • Incident hyperkalemia (K ≥5.5 mmol/L) (4 and 8 weeks)
  • Proportion of the correction of hypokalemia (from K <3.5 mmol/L to 3.5-5.0 mmol/L) (4 and 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-08
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 607 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins University
Collaborators: National Heart Foundation of Bangladesh, Vital Strategies
Principal Investigators:
  • Junichi Ishigami, MD, PhD (PRINCIPAL_INVESTIGATOR) - Johns Hopkins University
Contact Information
Study Contact:
Junichi Ishigami, MD, PhD
14432877262
jishiga1@jhu.edu
Sohel Reza Choudhury, MD, PhD
Sohel Reza Choudhury, MD, PhD
+880 9666-750075
sohel_r_choudhury@hotmail.com
The National Heart Foundation of Bangladesh
Interventions
  • Dietary Supplement: Low-sodium salt substitute — The low sodium salt substitute contains 25% potassium chloride (KCl range; 20%-35%)
Study Locations (1 sites)
The National Heart Foundation of Bangladesh, Dhaka, Bangladesh
Eligibility Criteria
Inclusion Criteria: * Adults ≥18 years with clinically diagnosed hypertension treated with medication \[on a stable dose at least for 2 months\] * Have a phone for contact Exclusion Criteria: * Those with baseline K ≥5.0 or K \<3.0 mmol/L * Advanced kidney disease (eGFR \<45 ml/min/1.73m2). * Those on potassium sparing diuretics (e.g., spironolactone) * Other medical conditions determined by physicians (e.g., heart failure treated with medication; life expectancy less than 12 months) * Dine out for dinner more than 3 times a week
Conditions Breast Cancer
Phase PHASE2
Enrollment 94
Locations 13 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if tinengotinib combined with fulvestrant works to treat patients with HR-Positive and HER-2-Negative or low-expressing advanced breast cancer. It will also learn about the safety of combination therapy. The main questions it aims to answer are: 1. Does tinengotinib combined with fulvestrant reduce the tumor burden in participants? 2. What medical problems do participants have when taking the combination therapy? Participants will: Take tinengotinib and fulvestrant to find the optimal dose of tinengotinib for the combination therapy in Part A. In Part B, will take tinengotinib at the optimal dose with fulvestrant or tinengotinib alone to see if the combination therapy works better than tinengotinib monotherapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Tinengotinib at the optimal dose combined with Fulvestrant — Participants will receive tinengotinib at the optimal dose once daily with fulvestrant in 28-day cycles per protocol defined schedule.
  • Drug: Tinengotinib — Participants will receive tinengotinib once daily in 28-day cycles per protocol defined schedule.
  • Drug: tinengotinib combined with fulvestrant — Participants will take tinengotinib at the starting dose of 10 mg once daily with fulvestrant to determine the optimal dose of tinengotinib in combination with fulvestrant. If not tolerated, the dose of tinengotinib will be reduced to 8 mg or 6 mg once daily.

Primary Outcomes

  • Part A: safety evaluation parameters (From signing of the informed consent until 28 days after the last dose or the end of the study (whichever occurs first), an average of 1 year.)
  • Part B: Objective Response Rate (ORR) (RECIST v1.1) (From first study drug administration to the end of treatment, an average of 1 year.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-03-17
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 94 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: TransThera Sciences (Nanjing), Inc.
Contact Information
Study Contact:
Caixia Sun
025-58216298
sun_caixia@transtherabio.com
Kun Wang, MD
Guangdong Provincial People's Hospital
Haijun Yu, MD
Zhongnan Hospital of Wuhan University
Interventions
  • Drug: Tinengotinib at the optimal dose combined with Fulvestrant — Participants will receive tinengotinib at the optimal dose once daily with fulvestrant in 28-day cycles per protocol defined schedule.
  • Drug: Tinengotinib — Participants will receive tinengotinib once daily in 28-day cycles per protocol defined schedule.
  • Drug: tinengotinib combined with fulvestrant — Participants will take tinengotinib at the starting dose of 10 mg once daily with fulvestrant to determine the optimal dose of tinengotinib in combination with fulvestrant. If not tolerated, the dose of tinengotinib will be reduced to 8 mg or 6 mg once daily.
Study Locations (13 sites)
Guangdong Provincial People's Hospital, Guangzhou, Guangdong China
Zhongnan Hospital of Wuhan University, Wuhan, Hubei China
Hunan Cancer Hospital, Changsha, Hunan China
Jiangsu Province Hospital, Nanjing, Jiangsu China
Shandong Cancer Hospital, Jinan, Shandong China
Linyi Cancer Hospital, Linyi, Shandong China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang China
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021 China
Beijing Cancer Hospital, Beijing, China
The First Medical Center, Chinese PLA General Hospital, Beijing, China
Eligibility Criteria
Inclusion Criteria: 1. Histologically or cytologically confirmed breast cancer with evidence of local recurrence or distant metastasis and no indication for surgery or radiotherapy; 2. Breast cancer confirmed as HR+/HER2- negative or low expression by local laboratory testing based on the most recent tumor tissue sample (from either the primary or metastatic site, excluding bone lesions). HR-positive, HER2-negative or low expression as defined in this study refer to the Chinese Society of Clinical Oncology \[CSCO\] 2024 criteria; 3. Participants must meet at least one of the following criteria: a) prior bilateral oophorectomy, or age ≥60 years; b) age \<60 years, with natural amenorrhea (in the absence of medication or pathological conditions) for ≥12 months, and estradiol and FSH levels within the postmenopausal range; c) age \<60 years, currently undergoing ovarian suppression therapy (e.g., LHRH agonist) and requiring continued treatment during the study, with estradiol and FSH levels maintained within the postmenopausal range; 4. Participants who have previously failed 1-2 lines of endocrine therapy (including AI, SERD, and SERM) for recurrent or metastatic disease are eligible. Subjects with initial diagnosis showing weak ER positivity by IHC (tumor cells with nuclear staining accounting for 1%-10%) are not eligible for enrollment; 5. Participants must have experienced disease progression after prior treatment with at least one CDK4/6 inhibitor (CDK4/6i), including in the neoadjuvant, adjuvant, or systemic treatment settings; 6. Participants who have previously failed 0-2 lines of systemic chemotherapy (cytotoxic drugs) for recurrent or metastatic disease. Antibody-drug conjugates (ADCs) are not counted as systemic chemotherapy; 7. ECOG ≤ 1; 8. Participants must meet at least one of the following criteria (per RECIST v1.1): a) At least one measurable lesion as defined by RECIST v1.1 at baseline; if the only target lesion is a non-nodal lesion, its longest diameter must be ≥15 mm; b) When bone lesions are the only measurable lesions, lytic or mixed bone lesions may be selected as target lesions; subjects with only blastic bone lesions are not eligible for enrollment. 9. Adequate organ and bone marrow function; 10. Premenopausal participants receiving ovarian suppression therapy must agree to use adequate contraception to avoid pregnancy during the study and for at least 3 months after the end of treatment; 11. Able to sign informed consent and comply with the protocol. Exclusion Criteria: 1. Participants who are pregnant or breastfeeding; 2. Conditions judged by the investigator as making the participant unsuitable for study drug treatment, including but not limited to: a history of severe allergy to the components or excipients of the study drug, prior treatment history with the study drug, or presence of complications that may be life-threatening in the short term (such as pleural, pericardial, or abdominopelvic effusions that cannot be controlled by drainage or other methods); 3. Uncontrolled hypertension (systolic blood pressure \>150 mmHg or diastolic blood pressure \>100 mmHg), allowing for the lowest value from up to two repeat measurements; 4. Participants with brain or central nervous system (CNS) metastases that have progressed as confirmed by imaging or clinically within 28 days before the start of treatment (e.g., evidence of new or enlarging brain metastases on imaging, new neurological symptoms attributable to brain/CNS metastases); 5. Participants with concurrent other malignancies or hematologic malignancies that are progressing or require active treatment (excluding basal cell carcinoma of the skin, other non-invasive or indolent malignancies, or cured tumors); Hormone replacement therapy is permitted (e.g., thyroxine replacement therapy post-thyroidectomy); 6. Participants who have received systemic treatment with corticosteroids (\>10 mg/day of prednisone or equivalent dose of other corticosteroids) or other immunosuppressive medications within 14 days prior to the initiation of the study drug; 7. Participants who have received other systemic anti-tumor therapies or treatment with investigational drugs prior to the initiation of the study drug, with a washout period of approximately 5 half-lives or 14 days, whichever is shorter; 8. Participants who have received extensive radiotherapy or major surgery within 4 weeks prior to the initiation of the study drug, or local palliative radiotherapy within 2 weeks. (If the investigator judges that this does not pose an additional safety risk, initiation of the study drug during the washout period may be permitted with sponsor agreement.) 9. Participants who have not yet recovered from adverse events resulting from prior anti-tumor therapy (excluding adverse events ≤ Grade 1 per CTCAE, or ≤ Grade 2 adverse events that the investigator judges do not pose a safety risk). 10. History of severe cardiac or cerebrovascular disease; 11. Participants who have severe gastrointestinal disease or gastrointestinal dysfunction that may lead to absorption, metabolism or excretion of the study drug, enrollment eligibility will be based on the investigator's judgment (including but not limited to total gastrotomy, short bowel syndrome). 12. Participants who have bleeding disorders or thrombotic disorders or therapeutic anticoagulant therapy requiring INR monitoring. 13. Participants who have received a strong CYP3A inhibitor and inducer before starting the study drug, within an interval of ≤ 2 weeks or 5 half-lives (whichever is shorter); 14. Tested positive for the human immunodeficiency virus (HIV); 15. Participants with active HBV infection and/or HCV infection; 16. Participants who are unable to swallow or tolerate oral medication. 17. The investigator determines that there are other reasons making the participant unsuitable for participation in the study.